Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Oncol Pharm Pract ; 17(3): 191-6, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20630921

RESUMEN

The Centralized Chemotherapy Reconstitution Unit (CCRU) of Paul Brousse Hospital Pharmacy Department assessed the reliability of its Cytotoxics Compounded Sterile Products (CCSP) preparation method in order to improve its CCSP quality assurance system. Five cytotoxic drugs - gemcitabine, 5-fluorouracil, docetaxel, paclitaxel, and oxaliplatin - were assayed by high performance liquid chromatography (HPLC) to determine CCSP concentration. During the observation period, 23,892 CCSP were prepared. Overall, 12,964 preparations contained one of the five analyzed drugs; 7382 (56.9%) out of 12,964 CCSP were analyzed by HPLC; 646 (8.8%) out of 7382 concentrations were outside ± 20% of the prescribed dose; 544 (84.2%) out of 646 were post-administration results and could not be verified. Out of 102 (15.8%) pre-administration results that were re-tested after re-shaking, 94 (92.2%) were found to be acceptable upon re-testing, and 8 (7.8%) were confirmed to be unacceptable and needed to be re-compounded. The 8.8% of tested CCSP were outside ± 20% of the prescribed dose, but extrapolating the results on re-tested CCSP, we can say that our CCSP preparation is reliable with an estimation of only 0.7% of 7382 CCSP analyzed, confirmed as being ± 20% outside the prescribed dose. Nevertheless, this ± 20% magnitude of error should be reduced. Based on pre-administration results, the primary cause of concentration errors appeared to be insufficient mixing of the finished product. Most CCSP dosages occurred after it had been administered, the organization should, therefore, be improved to include testing all CCSP prior to administration. Pharmaceutical companies should endeavor to manufacture compounded injectible drugs in a 'ready to use' form and provide vehicles in accurate volumes in order to improve compounding precision.


Asunto(s)
Antineoplásicos/normas , Cromatografía Líquida de Alta Presión/normas , Citotoxinas/normas , Contaminación de Medicamentos/prevención & control , Hospitales Universitarios/normas , Servicio de Farmacia en Hospital/normas , Antineoplásicos/administración & dosificación , Asepsia/normas , Citotoxinas/administración & dosificación , Composición de Medicamentos/normas , Francia , Humanos , Infusiones Intravenosas , Garantía de la Calidad de Atención de Salud/normas , Control de Calidad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Factores de Tiempo
2.
Arch Gerontol Geriatr ; 45(1): 65-71, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17303263

RESUMEN

The aim of this prospective study was to examine the relationship between IL-6 levels and survival in an elderly population in a long term hospital care ward. All of the 184 women and 65 men hospitalized in the geriatric unit regardless of their health status were included. The plasma levels of interleukin-6 were measured at baseline and deaths were assessed over a 2-year period. IL-6 levels of at least 3pg/ml in men and 5.6pg/ml in women were respectively associated with a relative risk of death of 2.28 (CI(95): 1.04-4.95) and 1.52 (CI(95): 1.06-2.18). After adjustment for age class, the reduced survival observed with these thresholds only remained unchanged in men, the difference in survival in women was not significant. Our conclusion is that even in an elderly hospitalized population, high IL-6 levels were associated with poor survival. The lower survival rate after adjustment for class of age found in men but not in women suggests a gender-related specificity.


Asunto(s)
Interleucina-6/sangre , Cuidados a Largo Plazo , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Estudios Transversales , Femenino , Anciano Frágil , Francia/epidemiología , Humanos , Masculino , Pronóstico , Estudios Retrospectivos , Factores Sexuales , Tasa de Supervivencia/tendencias
3.
Antimicrob Resist Infect Control ; 2(1): 18, 2013 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-23738672

RESUMEN

BACKGROUND: Vancomycin-resistant enterococci (VRE) are still a concern in hospital units tending to seriously ill patients. However, the cost-effectiveness of active surveillance program to identify asymptomatically VRE colonized patient remains debatable. This work aims at evaluating the cost of a failure in the active surveillance of VRE that had resulted in an outbreak in a French University Hospital. FINDINGS: A VRE outbreak was triggered by a failure in the systematic VRE screening in a medico-surgical ward specialised in liver transplantation as a patient was not tested for VRE. This failure was likely caused by the reduction of healthcare resource. The outbreak involved 13 patients. Colonized patients were grouped in a dedicated part of the infectious diseases unit and tended by a dedicated staff. Transmission was halted within two months after discovery of the index case.The direct cost of the outbreak was assessed as the cost of staffing, disposable materials, hygiene procedures, and surveillance cultures.The loss of income from spare isolation beds was computed by difference with the same period in the preceding year. Payments were drawn from the hospital database. The direct cost of the outbreak (2008 Euros) was €60 524 and the loss of income reached €110 915. CONCLUSIONS: Despite this failure, the rapid eradication of the VRE outbreak was a consequence of the rapid isolation of colonized patient. Yet, eradicating even a limited outbreak requires substantial efforts and resources. This underlines that special attention has to be paid to strictly adhere to active surveillance program.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA